Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Myriad Genetics (MYGN) Assets Average (2016 - 2025)

Myriad Genetics (MYGN) has disclosed Assets Average for 15 consecutive years, with $717.4 million as the latest value for Q4 2025.

  • On a quarterly basis, Assets Average fell 31.97% to $717.4 million in Q4 2025 year-over-year; TTM through Dec 2025 was $717.4 million, a 31.97% decrease, with the full-year FY2025 number at $867.1 million, down 20.23% from a year prior.
  • Assets Average was $717.4 million for Q4 2025 at Myriad Genetics, up from $702.7 million in the prior quarter.
  • In the past five years, Assets Average ranged from a high of $1.4 billion in Q1 2021 to a low of $702.7 million in Q3 2025.
  • A 5-year average of $1.1 billion and a median of $1.2 billion in 2023 define the central range for Assets Average.
  • Peak YoY movement for Assets Average: dropped 3.55% in 2023, then tumbled 31.97% in 2025.
  • Myriad Genetics' Assets Average stood at $1.3 billion in 2021, then decreased by 9.26% to $1.2 billion in 2022, then dropped by 4.77% to $1.1 billion in 2023, then dropped by 8.13% to $1.1 billion in 2024, then crashed by 31.97% to $717.4 million in 2025.
  • Per Business Quant, the three most recent readings for MYGN's Assets Average are $717.4 million (Q4 2025), $702.7 million (Q3 2025), and $841.7 million (Q2 2025).